ALMADEN GENOMICS NAMES BOARD OF ADVISORS
DALLAS, May 31, 2023 /PRNewswire/ -- Almaden Genomics has announced its Board of Advisors, a highly regarded group of healthcare leaders from both the public and private sectors with experience in cancer research, presicion medicine, biotechnology, clinical trials, bioinformatics, data visualization, computational analysis, pharmacology, and AI. The Board – which includes Adrian Lee, Ph.D., Samir Courdy; Rayna Herman; Graham Hughes, M.D.; and David Miller, Ph.D. – will help guide Almaden as it enables companies and labs to accelerate genomic discovery and drug development via its streamlined data analysis platform, g.nome™.
"Our first Board of Advisors is a team of respected industry giants upon whose shoulders we can embolden our existing team of talented bioinformaticians, engineers, and industry professionals," said David Gascoigne, Chief Executive Officer of Almaden Genomics. "Each brings an understanding of the drug discovery process that will not only help us as we build out and further improve upon g.nome, but to also connect our team with the labs and researchers for which g.nome can unlock new and promising solutions."
Graham Hughes, M.D.
Adrian Lee, Ph.D.
David Miller, Ph.D.
Dramatically accelerating bioinformatic development from months to mere hours, g.nome is a cloud-native data analysis platform from Almaden that enables pipeline iteration by scientists of all skill levels. From promising drug development, diagnosis of genetic disease, and the realization of personalized medicine, g.nome helps speed discovery in genomic research. It leverages an advanced visual drag-and-drop workflow builder and curated library of open-source tools, enabling users to have confidence in their results, get to market faster and scale profitably.
Launched in 2022, Almaden Genomics is the latest in a series of spinoffs by Catalyze Dallas to speed time-to-market for technology harvested from the Fortune 100. Catalyze launches scalable companies that accelerate commercialization of intellectual property sourced from the world's most innovative global corporations, unleashing the full value and potential of their investments in technology.
About Almaden Genomics
View original content to download multimedia:https://www.prnewswire.com/news-releases/almaden-genomics-names-board-of-advisors-301838670.html
SOURCE Almaden Genomics
The Power of AI in Business How to use Chat GPT with ERP
Keynote Panel: The Continued Rise of AI: Embracing the Known and Unknown to Drive Business Results
Understanding Both Sides of the M&A Paradigm